Literature DB >> 30323035

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.

Burcu Isler1, Yohei Doi2, Robert A Bonomo3,4, David L Paterson5.   

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for the investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process, accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late-stage preclinical studies for the treatment of CRAB, and it evaluates their expected benefits and potential shortcomings.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacterzzm321990; cefiderocol

Mesh：

Substances：

Year:  2018        PMID： 30323035      PMCID： PMC6325237          DOI： 10.1128/AAC.01110-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  82 in total

1.  Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.

Authors:  James M Regeimbal; Anna C Jacobs; Brendan W Corey; Matthew S Henry; Mitchell G Thompson; Rebecca L Pavlicek; Javier Quinones; Ryan M Hannah; Meron Ghebremedhin; Nicole J Crane; Daniel V Zurawski; Nimfa C Teneza-Mora; Biswajit Biswas; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.

Authors:  Robert K Flamm; Paul R Rhomberg; Ronald N Jones; David J Farrell
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.

Authors:  Harald Seifert; Danuta Stefanik; Joyce A Sutcliffe; Paul G Higgins
Journal:  Int J Antimicrob Agents       Date:  2017-07-11       Impact factor: 5.283

4.  Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.

Authors:  Rujipas Sirijatuphat; Visanu Thamlikitkul
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

5.  Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City.

Authors:  Marie Abdallah; Olawole Olafisoye; Christopher Cortes; Carl Urban; David Landman; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

6.  Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.

Authors:  J Dobias; V Dénervaud-Tendon; L Poirel; P Nordmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-26       Impact factor: 3.267

Review 7.  Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis.

Authors:  Oren Zusman; Sergey Altunin; Fidi Koppel; Yael Dishon Benattar; Habip Gedik; Mical Paul
Journal:  J Antimicrob Chemother       Date:  2016-09-13       Impact factor: 5.790

Review 8.  Combination therapy for carbapenem-resistant Gram-negative bacteria.

Authors:  Mical Paul; Yehuda Carmeli; Emanuele Durante-Mangoni; Johan W Mouton; Evelina Tacconelli; Ursula Theuretzbacher; Cristina Mussini; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2014-05-28       Impact factor: 5.790

9.  In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

10.  Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.

Authors:  H Aydemir; D Akduman; N Piskin; F Comert; E Horuz; A Terzi; F Kokturk; T Ornek; G Celebi
Journal:  Epidemiol Infect       Date:  2012-09-07       Impact factor: 4.434
View more
  64 in total

1.  A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development.

Authors:  Madeline R Galac; Erik Snesrud; Francois Lebreton; Jason Stam; Michael Julius; Ana C Ong; Rosslyn Maybank; Anthony R Jones; Yoon I Kwak; Kate Hinkle; Paige E Waterman; Emil P Lesho; Jason W Bennett; Patrick Mc Gann
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017.

Authors:  Sarah M McLeod; Samir H Moussa; Meredith A Hackel; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 3.  Gain and loss of antibiotic resistant genes in multidrug resistant bacteria: One Health perspective.

Authors:  Misung Kim; Jaeeun Park; Mingyeong Kang; Jihye Yang; Woojun Park
Journal:  J Microbiol       Date:  2021-04-20       Impact factor: 3.422

Review 4.  Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.

Authors:  David A Butler; Mark Biagi; Xing Tan; Samah Qasmieh; Zackery P Bulman; Eric Wenzler
Journal:  Curr Infect Dis Rep       Date:  2019-11-16       Impact factor: 3.725

5.  Molecular Characterization and Antibiotic Susceptibility Profile of Acinetobacter baumannii Recovered from Hospital Wastewater Effluents.

Authors:  Qaqamba Mapipa; Tennison Onoriode Digban; Nonso Emmanuel Nnolim; Nolonwabo Nontongana; Anthony Ifeanyi Okoh; Uchechukwu U Nwodo
Journal:  Curr Microbiol       Date:  2022-03-08       Impact factor: 2.188

6.  Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.

Authors:  Saquib Malik; Monica Kaminski; David Landman; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

7.  Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy.

Authors:  Nayara Helisandra Fedrigo; Danielle Rosani Shinohara; Josmar Mazucheli; Sheila Alexandra Belini Nishiyama; Floristher Elaine Carrara-Marroni; Frederico Severino Martins; Peijuan Zhu; Mingming Yu; Sherwin Kenneth B Sy; Maria Cristina Bronharo Tognim
Journal:  Sci Rep       Date:  2021-05-31       Impact factor: 4.379

8.  The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies.

Authors:  Alessia Savoldi; Elena Carrara; Laura J V Piddock; Francois Franceschi; Sally Ellis; Margherita Chiamenti; Damiano Bragantini; Elda Righi; Evelina Tacconelli
Journal:  BMC Infect Dis       Date:  2021-06-09       Impact factor: 3.090

9.  Short-Course Versus Long-Course Colistin for Treatment of Carbapenem-Resistant A.baumannii in Cancer Patient.

Authors:  Wasan Katip; Suriyon Uitrakul; Peninnah Oberdorfer
Journal:  Antibiotics (Basel)       Date:  2021-04-22

10.  Landscape of Multidrug-Resistant Gram-Negative Infections in Egypt: Survey and Literature Review.

Authors:  Amani El-Kholy; Hadir A El-Mahallawy; Noha Elsharnouby; Mohamed Abdel Aziz; Ahmed Mohamed Helmy; Ramy Kotb
Journal:  Infect Drug Resist       Date:  2021-05-24       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.